国产重组链激酶溶栓治疗急性心肌梗塞的临床观察  

A Clinical Observe on Thrombolysis with IntravenousRecombinant Streptokinase Made in China in Acute Myocardial Infarction

作　　者：李晓霞[1] 王毓华[1] 李惠民 郝应禄[1] 梁云清[1] 钱宝堂[1] 

机构地区：[1]大理学院玉溪教学医院心内科,云南玉溪653100 [2]玉溪市第三人民医院急诊科,云南玉溪653100

出　　处：《大理学院学报（医学版）》2002年第1期17-18,22,共3页

摘　　要：目的:观察国产重组链激酶(rSK)在急性心肌梗塞(AMI)静脉溶栓治疗的临床疗效和不良反应。方法:79例符合溶栓治疗的AMI患者,按用药情况分为rSK组30例和尿激酶(UK)组49例,观察冠状动脉再通率,出血并发症以及rSK的不良反应。结果:rSK组的临床血管再通率76.67%,显著高于UK组的55.10%(P<0.05)。两组出血并发症无显著性差异(P>0.05)。rSK组发生轻微过敏反应6.7%,低血压10.0%,对症治疗后迅速好转。结论:国产rSK溶栓治疗AMI,血管再通率高,不良反应发生率低,程度轻,为一安全有效的溶栓药物。Objective:To Observe the clinical efficacy and adverse reaction of intravenous thrombolytic therapy using Recombinant Streptokinase(rSK) made in china in acute myocardical infarction(AMI).Methods:79 patients with Acute Myocardial Infaction.30 patients were treated with intravenous rSK and 49 patients were treated with UK.To abserve the patency of infarct-related coronary artery and reaction of rSK.Results:The patency of using rSK was 76.67%.It was higher than using UK(the rate was 55.10%)(P<0.05).The bleeding complication havn't obvious imparity between two groups(P>0.05).The rate of allergic reaction was 6.7%and hypotension was 10.0%ih using the rSK group.All recoverd after therapy.Conclusions:These data suggest rSK made in china is an effective and safe thrombolytic agent.

关 键 词：重组链激酶 心肌梗塞 溶栓治疗 

分 类 号：R542.2+2[医药卫生—心血管疾病]